{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T08:27:46Z","timestamp":1793262466794,"version":"4.5.0"},"reference-count":27,"publisher":"Public Library of Science (PLoS)","issue":"12","license":[{"start":{"date-parts":[[2020,12,28]],"date-time":"2020-12-28T00:00:00Z","timestamp":1609113600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"abstract":"<jats:p>\n                    Achondroplasia is a rare genetic disorder caused by mutations in the Fibroblast Growth Factor receptor 3 (FGFR3). These mutations lead to aberrant increase of inhibitory signaling in proliferating chondrocytes at the growth plate. Recifercept is a potential treatment for this disease using a decoy approach to sequester FGFR3 ligands subsequently normalizing activation of the mutated FGFR3 receptor. Recifercept binds to FGF isoforms\n                    <jats:italic>in vitro<\/jats:italic>\n                    and in cellular model systems and reduces FGFR3 signaling. In addition, in a transgenic mouse model of achondroplasia, Recifercept restores reduced body weight and long bone growth in these mice. These data suggest that Recifercept treatment could lead to clinical benefits in children treated with this molecule.\n                  <\/jats:p>","DOI":"10.1371\/journal.pone.0244368","type":"journal-article","created":{"date-parts":[[2020,12,28]],"date-time":"2020-12-28T14:40:02Z","timestamp":1609166402000},"page":"e0244368","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":33,"title":["In vitro and in vivo characterization of Recifercept, a soluble fibroblast growth factor receptor 3, as treatment for achondroplasia"],"prefix":"10.1371","volume":"15","author":[{"given":"Diogo","family":"Gon\u00e7alves","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guyl\u00e8ne","family":"Rignol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre","family":"Dellugat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guido","family":"Hartmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie","family":"Sarrazy Garcia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey","family":"Stavenhagen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Santarelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elvire","family":"Gouze","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7746-0134","authenticated-orcid":true,"given":"Christian","family":"Czech","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2020,12,28]]},"reference":[{"issue":"2","key":"pone.0244368.ref001","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1007\/s11914-017-0347-2","article-title":"Current Care and Investigational Therapies in Achondroplasia","volume":"15","author":"S Unger","year":"2017","journal-title":"Curr Osteoporos Rep"},{"issue":"2","key":"pone.0244368.ref002","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/0092-8674(94)90302-6","article-title":"Mutations in the transmembrane domain of FGFR3 cause the most common genetic form of dwarfism, achondroplasia","volume":"78","author":"R Shiang","year":"1994","journal-title":"Cell"},{"issue":"2","key":"pone.0244368.ref003","first-page":"368","article-title":"Achondroplasia is defined by recurrent G380R mutations of FGFR3","volume":"56","author":"GA Bellus","year":"1995","journal-title":"Am J Hum Genet"},{"issue":"2","key":"pone.0244368.ref004","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.cytogfr.2005.02.003","article-title":"FGF signaling in the developing endochondral skeleton","volume":"16","author":"DM Ornitz","year":"2005","journal-title":"Cytokine Growth Factor Rev"},{"issue":"4","key":"pone.0244368.ref005","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1038\/ng0496-390","article-title":"Skeletal overgrowth and deafness in mice lacking fibroblast growth factor receptor 3","volume":"12","author":"JS Colvin","year":"1996","journal-title":"Nat Genet"},{"issue":"24","key":"pone.0244368.ref006","doi-asserted-by":"crossref","first-page":"4977","DOI":"10.1242\/dev.125.24.4977","article-title":"Repression of hedgehog signaling and BMP4 expression in growth plate cartilage by fibroblast growth factor receptor 3","volume":"125","author":"MC Naski","year":"1998","journal-title":"Development"},{"issue":"11","key":"pone.0244368.ref007","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1359\/jbmr.1999.14.11.1909","article-title":"Skeletal dysplasia and defective chondrocyte differentiation by targeted overexpression of fibroblast growth factor 9 in transgenic mice","volume":"14","author":"S Garofalo","year":"1999","journal-title":"J Bone Miner Res"},{"issue":"1","key":"pone.0244368.ref008","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13023-018-0972-6","article-title":"Achondroplasia: a comprehensive clinical review","volume":"14","author":"RM Pauli","year":"2019","journal-title":"Orphanet J Rare Dis"},{"issue":"7","key":"pone.0244368.ref009","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1007\/s00431-017-2923-y","article-title":"Final adult height in long-term growth hormone-treated achondroplasia patients","volume":"176","author":"D Harada","year":"2017","journal-title":"Eur J Pediatr"},{"issue":"1","key":"pone.0244368.ref010","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1056\/NEJMoa1813446","article-title":"C-Type Natriuretic Peptide Analogue Therapy in Children with Achondroplasia","volume":"381","author":"R Savarirayan","year":"2019","journal-title":"N Engl J Med"},{"issue":"3","key":"pone.0244368.ref011","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1124\/jpet.119.258251","article-title":"TransCon CNP, a Sustained-Release C-Type Natriuretic Peptide Prodrug, a Potentially Safe and Efficacious New Therapeutic Modality for the Treatment of Comorbidities Associated with Fibroblast Growth Factor Receptor 3-Related Skeletal Dysplasias","volume":"370","author":"VM Breinholt","year":"2019","journal-title":"J Pharmacol Exp Ther"},{"issue":"1","key":"pone.0244368.ref012","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/s10195-019-0541-3","article-title":"Limb lengthening history, evolution, complications and current concepts","volume":"21","author":"GA Hosny","year":"2020","journal-title":"J Orthop Traumatol"},{"issue":"2","key":"pone.0244368.ref013","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1128\/MCB.20.2.516-522.2000","article-title":"The transmembrane mutation G380R in fibroblast growth factor receptor 3 uncouples ligand-mediated receptor activation from down-regulation","volume":"20","author":"E Monsonego-Ornan","year":"2000","journal-title":"Mol Cell Biol"},{"issue":"2","key":"pone.0244368.ref014","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.bone.2006.11.030","article-title":"Sustained phosphorylation of mutated FGFR3 is a crucial feature of genetic dwarfism and induces apoptosis in the ATDC5 chondrogenic cell line via PLCgamma-activated STAT1","volume":"41","author":"D Harada","year":"2007","journal-title":"Bone"},{"issue":"203","key":"pone.0244368.ref015","doi-asserted-by":"crossref","first-page":"203ra124","DOI":"10.1126\/scitranslmed.3006247","article-title":"Postnatal soluble FGFR3 therapy rescues achondroplasia symptoms and restores bone growth in mice","volume":"5","author":"S Garcia","year":"2013","journal-title":"Sci Transl Med"},{"key":"pone.0244368.ref016","doi-asserted-by":"crossref","first-page":"d781","DOI":"10.2741\/A321","article-title":"FGF signaling in skeletal development","volume":"3","author":"MC Naski","year":"1998","journal-title":"Front Biosci"},{"issue":"5","key":"pone.0244368.ref017","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1172\/JCI38017","article-title":"Antibody-based targeting of FGFR3 in bladder carcinoma and t(4;14)-positive multiple myeloma in mice","volume":"119","author":"J Qing","year":"2009","journal-title":"J Clin Invest"},{"issue":"1","key":"pone.0244368.ref018","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.yexcr.2004.03.011","article-title":"FGF2 inhibits proliferation and alters the cartilage-like phenotype of RCS cells","volume":"297","author":"P Krejci","year":"2004","journal-title":"Exp Cell Res"},{"issue":"3","key":"pone.0244368.ref019","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1073\/pnas.97.3.1113","article-title":"Up-regulation of the chondrogenic Sox9 gene by fibroblast growth factors is mediated by the mitogen-activated protein kinase pathway","volume":"97","author":"S Murakami","year":"2000","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"3","key":"pone.0244368.ref020","doi-asserted-by":"crossref","first-page":"REVIEWS3005","DOI":"10.1186\/gb-2001-2-3-reviews3005","article-title":"Fibroblast growth factors","volume":"2","author":"DM Ornitz","year":"2001","journal-title":"Genome Biol"},{"key":"pone.0244368.ref021","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/978-1-4614-0887-1_1","article-title":"The structural biology of the FGF19 subfamily","volume":"728","author":"A Beenken","year":"2012","journal-title":"Adv Exp Med Biol"},{"issue":"6937","key":"pone.0244368.ref022","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1038\/nature01657","article-title":"Developmental regulation of the growth plate","volume":"423","author":"HM Kronenberg","year":"2003","journal-title":"Nature"},{"issue":"2","key":"pone.0244368.ref023","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.cytogfr.2005.01.001","article-title":"Cellular signaling by fibroblast growth factor receptors","volume":"16","author":"VP Eswarakumar","year":"2005","journal-title":"Cytokine Growth Factor Rev"},{"issue":"2","key":"pone.0244368.ref024","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/j.yexcr.2004.11.012","article-title":"Cell responses to FGFR3 signalling: growth, differentiation and apoptosis","volume":"304","author":"CG L'Hote","year":"2005","journal-title":"Exp Cell Res"},{"issue":"14","key":"pone.0244368.ref025","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1101\/gad.266551.115","article-title":"Fibroblast growth factor signaling in skeletal development and disease","volume":"29","author":"DM Ornitz","year":"2015","journal-title":"Genes Dev"},{"issue":"6","key":"pone.0244368.ref026","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1016\/j.bone.2005.03.006","article-title":"Complementary antagonistic actions between C-type natriuretic peptide and the MAPK pathway through FGFR-3 in ATDC5 cells","volume":"36","author":"A Ozasa","year":"2005","journal-title":"Bone"},{"issue":"6","key":"pone.0244368.ref027","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1016\/j.ajhg.2012.10.014","article-title":"Evaluation of the therapeutic potential of a CNP analog in a Fgfr3 mouse model recapitulating achondroplasia","volume":"91","author":"F Lorget","year":"2012","journal-title":"Am J Hum Genet"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0244368","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,9]],"date-time":"2022-12-09T13:31:44Z","timestamp":1670592704000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0244368"}},"subtitle":[],"editor":[{"given":"Dominique","family":"Heymann","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2020,12,28]]},"references-count":27,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2020,12,28]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0244368","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,12,28]]}}}